The closely contested odds around 52.5% Yes for California Proposition 38 reflect voter weighing of potential advances in immunology and immunotherapy research for cancer, heart disease, and Alzheimer’s against the measure’s fiscal and structural features. The $8.4 billion general obligation bond would direct roughly half the funds to a single University of California-affiliated institute under narrow criteria, with the rest allocated via competitive grants, while requiring treatment price discounts and repayment from the state General Fund at an estimated $500 million annually for 25 years. Trader balance stems from support tied to research priorities amid federal funding pressures offset by scrutiny over concentrated allocation and long-term debt service. Recent polling trends, campaign spending disclosures, or shifts in state revenue projections could tip sentiment ahead of the November 3, 2026 vote.